Compare CVE & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVE | KVUE |
|---|---|---|
| Founded | 2009 | 2022 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Specialty Chemicals |
| Sector | Energy | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 34.9B |
| IPO Year | N/A | 2023 |
| Metric | CVE | KVUE |
|---|---|---|
| Price | $22.60 | $18.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $26.00 | $19.73 |
| AVG Volume (30 Days) | 14.5M | ★ 41.1M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | 2.47% | ★ 4.51% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | N/A | $4.80 |
| Revenue Next Year | $5.69 | $2.52 |
| P/E Ratio | ★ $18.07 | $24.20 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.23 | $14.02 |
| 52 Week High | $23.89 | $25.17 |
| Indicator | CVE | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 59.23 | 47.53 |
| Support Level | $16.39 | $16.73 |
| Resistance Level | $23.39 | $19.07 |
| Average True Range (ATR) | 0.76 | 0.36 |
| MACD | -0.10 | -0.12 |
| Stochastic Oscillator | 49.02 | 20.40 |
Cenovus Energy Inc is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 786 thousand barrels of oil equivalent per day in 2022. The company had upstream projects across Western Canada; crude oil production and natural gas and NGLs production offshore China and Indonesia. The downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.